Eupraxia Pharmaceuticals Inc.
EPRXF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $28 | $17 | $10 | $1 |
| G&A Expenses | $0 | $6 | $9 | $1 |
| SG&A Expenses | $10 | $6 | $9 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $38 | $23 | $19 | $2 |
| Operating Income | -$38 | -$23 | -$21 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$5 | -$2 |
| Pre-Tax Income | -$38 | -$24 | -$23 | -$4 |
| Tax Expense | -$0 | $1 | -$1 | $2 |
| Net Income | -$38 | -$23 | -$23 | -$4 |
| % Margin | – | – | – | – |
| EPS | -1.58 | -1.21 | -1.61 | -0.31 |
| % Growth | -30.6% | 24.8% | -419.4% | – |
| EPS Diluted | -1.58 | -1.21 | -1.61 | -0.31 |
| Weighted Avg Shares Out | 24 | 19 | 14 | 13 |
| Weighted Avg Shares Out Dil | 24 | 19 | 14 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $2 | $2 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$37 | -$22 | -$21 | -$2 |
| % Margin | – | – | – | – |